Does the media prefer ABCL or CADL?

In the previous week, AbCellera Biologics had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for AbCellera Biologics and 5 mentions for Candel Therapeutics. AbCellera Biologics' average media sentiment score of 0.65 beat Candel Therapeutics' score of 0.63 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CADL or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$1.41 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is CADL or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -76.98% -48.50% Gemini Therapeutics N/A -38.78% -35.88%

Does the media favor CADL or QURE?

In the previous week, Candel Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 5 mentions for Candel Therapeutics and 3 mentions for uniQure. uniQure's average media sentiment score of 1.21 beat Candel Therapeutics' score of 0.63 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CADL or VCYT?

In the previous week, Veracyte had 9 more articles in the media than Candel Therapeutics. MarketBeat recorded 14 mentions for Veracyte and 5 mentions for Candel Therapeutics. Veracyte's average media sentiment score of 1.08 beat Candel Therapeutics' score of 0.63 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CLDX or CADL more profitable?

Celldex Therapeutics' return on equity of -52.35% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Celldex Therapeutics N/A -52.35% -47.61% Candel Therapeutics N/A -76.98% -48.50%

Does the media favor CLDX or CADL?

In the previous week, Candel Therapeutics had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Candel Therapeutics and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.19 beat Candel Therapeutics' score of 0.63 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Candel Therapeutics (CADL) Competitors

$13.07 -0.68 (-4.95%)

As of 08/28/2026 04:00 PM Eastern

Compare

CADL vs. ABCL, GMTX, QURE, VCYT, and CLDX

Should you buy Candel Therapeutics stock or one of its competitors? Candel Therapeutics's main competitors and comparable companies include AbCellera Biologics (ABCL), Gemini Therapeutics (GMTX), uniQure (QURE), Veracyte (VCYT), and Celldex Therapeutics (CLDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Candel Therapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Candel Therapeutics (NASDAQ:CADL) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Candel Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Candel Therapeutics	N/A	-76.98%	-48.50%

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Candel Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	46.32	-$146.41M	-$0.54	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

AbCellera Biologics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market.

In the previous week, AbCellera Biologics had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for AbCellera Biologics and 5 mentions for Candel Therapeutics. AbCellera Biologics' average media sentiment score of 0.65 beat Candel Therapeutics' score of 0.63 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics presently has a consensus target price of $12.83, indicating a potential upside of 13.07%. Candel Therapeutics has a consensus target price of $19.29, indicating a potential upside of 47.56%. Given Candel Therapeutics' higher possible upside, analysts clearly believe Candel Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

AbCellera Biologics beats Candel Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Candel Therapeutics compare to Gemini Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Candel Therapeutics currently has a consensus target price of $19.29, indicating a potential upside of 47.56%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Candel Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Candel Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics' return on equity of -38.78% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Gemini Therapeutics	N/A	-38.78%	-35.88%

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Candel Therapeutics had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Candel Therapeutics and 0 mentions for Gemini Therapeutics. Candel Therapeutics' average media sentiment score of 0.63 beat Gemini Therapeutics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Candel Therapeutics	Positive
Gemini Therapeutics	Neutral

Summary

Candel Therapeutics beats Gemini Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Candel Therapeutics compare to uniQure?

Candel Therapeutics (NASDAQ:CADL) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Candel Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Candel Therapeutics' return on equity of -76.98% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
uniQure	-1,350.73%	-111.96%	-29.01%

Candel Therapeutics presently has a consensus price target of $19.29, suggesting a potential upside of 47.56%. uniQure has a consensus price target of $65.00, suggesting a potential upside of 33.42%. Given Candel Therapeutics' higher possible upside, analysts clearly believe Candel Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

Candel Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the broader market. Comparatively, uniQure has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Candel Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
uniQure	$16.10M	209.92	-$198.97M	-$4.01	N/A

In the previous week, Candel Therapeutics had 2 more articles in the media than uniQure. MarketBeat recorded 5 mentions for Candel Therapeutics and 3 mentions for uniQure. uniQure's average media sentiment score of 1.21 beat Candel Therapeutics' score of 0.63 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Candel Therapeutics beats uniQure on 8 of the 15 factors compared between the two stocks.

How does Candel Therapeutics compare to Veracyte?

Candel Therapeutics (NASDAQ:CADL) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

13.9% of Candel Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 1.6% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Veracyte has a net margin of 20.37% compared to Candel Therapeutics' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Veracyte	20.37%	9.26%	8.61%

Candel Therapeutics has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

In the previous week, Veracyte had 9 more articles in the media than Candel Therapeutics. MarketBeat recorded 14 mentions for Veracyte and 5 mentions for Candel Therapeutics. Veracyte's average media sentiment score of 1.08 beat Candel Therapeutics' score of 0.63 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Veracyte	$561.90M	6.20	$66.35M	$1.41	30.74

Candel Therapeutics currently has a consensus price target of $19.29, suggesting a potential upside of 47.56%. Veracyte has a consensus price target of $54.33, suggesting a potential upside of 25.37%. Given Candel Therapeutics' higher possible upside, equities analysts plainly believe Candel Therapeutics is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Veracyte beats Candel Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Candel Therapeutics compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Candel Therapeutics (NASDAQ:CADL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Celldex Therapeutics currently has a consensus target price of $56.08, indicating a potential upside of 43.36%. Candel Therapeutics has a consensus target price of $19.29, indicating a potential upside of 47.56%. Given Candel Therapeutics' higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Candel Therapeutics has lower revenue, but higher earnings than Celldex Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,994.87	-$258.76M	-$4.35	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Celldex Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, suggesting that its share price is 151% less volatile than the broader market.

Celldex Therapeutics' return on equity of -52.35% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Candel Therapeutics	N/A	-76.98%	-48.50%

13.9% of Candel Therapeutics shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Candel Therapeutics had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Candel Therapeutics and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.19 beat Candel Therapeutics' score of 0.63 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celldex Therapeutics beats Candel Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Candel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CADL vs. The Competition

Export

Metric	Candel Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.00B	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-9.27	11.62	273.16	25.45
Price / Sales	N/A	1,359.72	625.22	90.88
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	7.92	16.53	12.98	6.14
Net Income	-$38.18M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-0.46%	-0.31%	0.13%	-0.80%
1 Month Performance	32.42%	9.80%	7.08%	4.13%
1 Year Performance	125.73%	55.66%	24.67%	15.17%

Candel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CADL Candel Therapeutics	2.9249 of 5 stars	$13.07 -4.9%	$19.29 +47.6%	+125.7%	$1.00B	N/A	N/A	60
ABCL AbCellera Biologics	2.8392 of 5 stars	$11.20 -1.6%	$12.83 +14.6%	+171.5%	$3.49B	$66.17M	N/A	500
GMTX Gemini Therapeutics	N/A	$78.84 -1.5%	N/A	+33.5%	$3.42B	N/A	N/A	30
QURE uniQure	3.1338 of 5 stars	$47.97 -1.3%	$65.00 +35.5%	+198.3%	$3.37B	$16.10M	N/A	500	Positive News
VCYT Veracyte	4.4877 of 5 stars	$42.08 +2.0%	$54.33 +29.1%	+42.8%	$3.32B	$561.90M	29.84	790	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CADL) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Candel Therapeutics (CADL) Competitors

CADL vs. ABCL, GMTX, QURE, VCYT, and CLDX

How does Candel Therapeutics compare to AbCellera Biologics?

Summary

How does Candel Therapeutics compare to Gemini Therapeutics?

Summary

How does Candel Therapeutics compare to uniQure?

Summary

How does Candel Therapeutics compare to Veracyte?

Summary

How does Candel Therapeutics compare to Celldex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Candel Therapeutics (CADL) Competitors

CADL vs. ABCL, GMTX, QURE, VCYT, and CLDX

How does Candel Therapeutics compare to AbCellera Biologics?

Is ABCL or CADL more profitable?

Do insiders and institutionals believe in ABCL or CADL?

Which has preferable valuation and earnings, ABCL or CADL?

Which has more risk & volatility, ABCL or CADL?

Does the media prefer ABCL or CADL?

Do analysts prefer ABCL or CADL?

Summary

How does Candel Therapeutics compare to Gemini Therapeutics?

Do analysts recommend CADL or GMTX?

Which has more risk & volatility, CADL or GMTX?

Which has higher valuation and earnings, CADL or GMTX?

Is CADL or GMTX more profitable?

Do institutionals & insiders believe in CADL or GMTX?

Does the media favor CADL or GMTX?

Summary

How does Candel Therapeutics compare to uniQure?

Is CADL or QURE more profitable?

Do analysts recommend CADL or QURE?

Which has more volatility and risk, CADL or QURE?

Which has preferable earnings and valuation, CADL or QURE?

Does the media favor CADL or QURE?

Do insiders and institutionals have more ownership in CADL or QURE?

Summary

How does Candel Therapeutics compare to Veracyte?

Do insiders and institutionals hold more shares of CADL or VCYT?

Is CADL or VCYT more profitable?

Which has more volatility & risk, CADL or VCYT?

Does the media prefer CADL or VCYT?

Which has stronger valuation and earnings, CADL or VCYT?

Do analysts rate CADL or VCYT?

Summary

How does Candel Therapeutics compare to Celldex Therapeutics?

Do analysts recommend CLDX or CADL?

Which has preferable valuation & earnings, CLDX or CADL?

Which has more risk and volatility, CLDX or CADL?

Is CLDX or CADL more profitable?

Do insiders & institutionals have more ownership in CLDX or CADL?

Does the media favor CLDX or CADL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools